MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$11,604K
Free Cash flow
-$18,068K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of short-term investm...
Deferred revenue
Accrued liabilities and other lo...
Others
Negative Cash Flow Breakdown
Purchases of short-term investme...
Accounts receivable
Prepaid expenses and other asset...
Accretion of discounts on short-...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-20,666
-18,248
-26,510
-14,229
Amortization of intangible assets
36
37
37
36
Depreciation and amortization
11
214
473
98
Impairment loss on machinery and equipment
-
-
-402
-
Accretion of discounts on short-term investments
1,428
726
719
636
Stock-based compensation expense
2,577
4,706
1,479
1,384
Non-cash lease expense
-1,365
-1,132
-1,161
-1,133
Accounts receivable
36,848
-1,367
384
-240
Prepaid expenses and other assets
2,859
887
874
-708
Accounts payable
571
67
655
419
Accrued liabilities and other long-term liabilities
3,338
-3,599
486
-326
Deferred revenue
35,835
-9,612
551
-4,375
Net cash used in operating activities
-18,068
-25,549
-23,243
-15,548
Purchases of property and equipment
0
0
201
-127
Purchases of short-term investments
69,047
242,777
44,218
19,688
Maturities of short-term investments
75,000
50,000
30,000
20,000
Net cash used in investing activities
5,953
-192,777
-14,419
439
Proceeds from issuance of pre-funded warrants, net of issuance cost
0
5,855
0
-
Proceeds from issuance of common stock, net issuance cost
56
228,351
16,262
0
Proceeds from employee stock purchase plan and exercise of stock options
455
281
381
253
Net cash provided by financing activities
511
234,487
16,643
253
Net increase in cash, cash equivalents and restricted cash
-11,604
16,161
-21,019
-14,856
Cash, cash equivalents and restricted cash, beginning of period
30,355
14,194
35,213
39,079
Cash, cash equivalents and restricted cash, end of period
18,751
30,355
14,194
35,213
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of short-term
investments
$75,000K
(-9.64%↓ Y/Y)
Proceeds from employee
stock purchase plan...
$455K
(157.06%↑ Y/Y)
Proceeds from issuance of
common stock, net...
$56K
(-99.94%↓ Y/Y)
Net cash used in
investing activities
$5,953K
(113.01%↑ Y/Y)
Net cash provided by
financing activities
$511K
(-99.45%↓ Y/Y)
Canceled cashflow
$69,047K
Net increase in
cash, cash...
-$11,604K
(-205.59%↓ Y/Y)
Canceled cashflow
$6,464K
Deferred revenue
$35,835K
(158.01%↑ Y/Y)
Accrued liabilities and
other long-term...
$3,338K
(204.02%↑ Y/Y)
Stock-based compensation
expense
$2,577K
(-25.07%↓ Y/Y)
Non-cash lease expense
-$1,365K
(37.64%↑ Y/Y)
Accounts payable
$571K
(166.94%↑ Y/Y)
Amortization of intangible
assets
$36K
(-50.68%↓ Y/Y)
Depreciation and
amortization
$11K
(-98.33%↓ Y/Y)
Purchases of short-term
investments
$69,047K
(-46.32%↓ Y/Y)
Net cash used in
operating activities
-$18,068K
(50.90%↑ Y/Y)
Canceled cashflow
$43,733K
Accounts receivable
$36,848K
(3086.06%↑ Y/Y)
Net income (loss)
-$20,666K
(-188.43%↓ Y/Y)
Prepaid expenses and
other assets
$2,859K
(165.71%↑ Y/Y)
Accretion of discounts on
short-term investments
$1,428K
(67.80%↑ Y/Y)
Buy us a coffee
CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. (CTMX)